Abigail Brooks, MA

Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.

Our March 2024 month in review highlights HCPLive’s top coverage of the latest news in nephrology, ranging from new CKD research and KDIGO guidelines to recent IgAN data.

Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.

SZN-043 showed evidence of target engagement, Wnt signal activation, and effects on liver function, supporting its advancement to a phase 1b trial in severe alcohol-associated hepatitis.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.

Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.

Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.

Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.

Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.

Vadadustat tablets are now approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for ≥ 3 months.

The post-hoc analysis found tenapanor significantly improved weekly scores for abdominal pain, discomfort, and bloating, as measured by the Abdominal Score.

A hypothetical triennial blood-based screening test meeting Centers for Medicare and Medicaid Services coverage criteria was cost-effective versus no screening but not compared to FIT, sDNA-FIT, or colonoscopy.

Patients with cirrhosis had greater health care costs than matched controls, attributed mostly to cirrhosis complications and high inpatient utilization in the first year after diagnosis.

Both high blood pressure and triglycerides were identified as risk factors for IgAN, although high blood pressure was deemed to have the most direct influence.

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Findings underscore the importance of considering both the serum IgA/C3 ratio and glomerular C3 staining in the management and treatment of IgAN.

The phase 2, proof-of-concept LEGEND trial achieved its primary efficacy endpoint for absolute reduction in HbA1c at week 24 with lanifibranor alone or in combination with empagliflozin.

Findings highlight non-inferiority for major morbidity and reduced detection of grade B or C POPF among patients who did not receive prophylactic passive abdominal drainage.

Previous reports suggest poor and unchanging rates of deceased kidney donation, though use of a recent metric for deaths compatible with donation yielded positive trends from 2003-2021.

A recent survey found telemedicine-based HCV treatment at a syringe access program could improve access to treatment among people who inject drugs.

Harrison discusses the role of GLP-1-based therapies in NASH management and situations where resmetirom may be a better option following its recent FDA approval.

Harrison discusses important lessons from obeticholic acid’s FDA failure and what set resmetirom apart from its predecessor, poising it to become the first FDA-approved NASH treatment.

Urinary miR-92a-3p, miR-425-5p, and miR-185-5p were significantly increased in patients with IgAN and were all associated with tubular atrophy/interstitial fibrosis.

Curtis discusses findings from her recent health economic study about the cost-effectiveness of treating perinatal HCV earlier, a growing concern amid rising rates of HCV in reproductive-aged adults.

Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.

In a landmark decision, the FDA has granted accelerated approval to resmetirom (Rezdiffra) for noncirrhotic NASH with moderate to advanced fibrosis.

To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.

Results showed the cell-free DNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions.

Saeed Mohammed, MD, MS, discusses maralixibat for pruritus in PFIC, describing how IBAT inhibitors have changed the way clinicians are able to treat cholestatic liver disease.